Accordingly, we expect that including compounds that target these pathways in combination with BET inhibitors may sensitize otherwise resistant tumors to BET inhibition and expand the current chemotherapeutic repertoire for HNSCC treatment. Here, DNER is linked to head and neck squamous cell carcinoma.